NanoSphere Health Offers Six-Fold Improvement in Cannabinoid Bioavailability
February 14th, 2018
Exclusive, News, Top News
The U.S. cannabis industry is projected to exceed $50 billion in size over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis in California and other states. While there are many opportunities for investors in the space, since they generate high-margin licensing revenue and don’t touch the plant, biotech firms developing innovative delivery mechanisms offer investors a compelling opportunity.
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) has developed an innovative delivery technology that solves key issues related to cannabinoid bioavailability. With an existing licensing agreement, the company is also well on its way to commercialization after spending more than a decade fine-tuning its technology–and developing products that have applications across an array of industries. Investors may want to take a closer look at the stock as a potential opportunity in the space.
The issue of bioavailability is a major problem facing the medical cannabis industry. In a 2009 study, researchers found that cannabinoid bioavailability ranged from 2-56 percent for inhaled cannabis smoke and from 4-20 percent for orally consumed cannabis products. This variability among patients makes it difficult for physicians to prescribe cannabinoid-based products.
On a broader level, pharmaceutical industry experts estimate that approximately 40 percent of lipophilic (fat-soluble) medications fail in clinical trials because of their lack of water solubility and formulation instability. The insolubility, degeneration by digestive enzymes, pre-systemic metabolism, poor intestinal absorption, and removal from the liver prevents them from reaching threshold levels for activity. To a great extent, this first-pass metabolism also affects cannabinoid absorption.
Many companies have started developing cannabinoid delivery mechanisms aimed at improving bioavailability. But it’s a challenging task that requires extensive research and development. After developing these delivery mechanisms, they must also work to integrate them with existing cannabinoid products, which requires the participation of other cannabis industry participants. These challenges have left a gaping hole in the market for a reliable solution.
Researchers at NanoSphere Health have spent the past decade developing its patent-pending NanoSphere Delivery System™. The product successfully addresses the absorption issues associated with a wide variety of products, such as nutraceuticals, pharmaceuticals, over-the-counter medications, phytonutrients, and cannabinoids. Only recently did the company decide to enter the burgeoning cannabis industry, where its technology adapts seamlessly as a solution to questions surrounding pharmaceutical bioavailability.
The evidence-based NanoSphere Delivery System™ provides up to six times the bioavailability of conventional cannabinoids by transporting active ingredients directly into the bloodstream and cells using patent-pending natural lipid nanoparticle structures. In addition to the bioavailability improvements, the platform offers a high degree of biocompatibility, versatility, efficacy, and safety that makes it a natural choice for industry participants.
On January 23, the company announced that it signed an agreement to license its technology in the State of California. The Oakland-based licensee is a private-label manufacturer of pharmaceutical goods for more than 35 leading brands in the legal cannabis space and the agreement provides the manufacturer with a non-exclusive license to the patent-pending NanoSphere Delivery System™ and its branded Evolve NanoSerum line.
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) represents a compelling investment opportunity in the legal cannabis industry. In addition to solving key issues relating to bioavailability, the company has already started to see some commercial wins after signing a deal with a large private-label manufacturer of pharmaceutical goods for more than 35 leading cannabis brands in the State of California.
Investors may want to take a closer look at the stock as a potential opportunity in the burgeoning cannabis industry, and in particular, California’s rapidly growing market.
For more information, visit the company’s website at www.nanospherehealth.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: https://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.